Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28
| Autor: | Alexa B. Kimball, Kristian Reich, Melinda Gooderham, S. K. Tyring, Kim Papp, Stuart A. Green, C. La Rosa, Diamant Thaçi, Rodney Sinclair, Qing Li, Andrew Blauvelt, Nicole Cichanowitz |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male medicine.medical_specialty Tildrakizumab Dermatology Placebo Antibodies Monoclonal Humanized Severity of Illness Index law.invention Etanercept Placebos 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Randomized controlled trial Psoriasis Area and Severity Index law Psoriasis Internal medicine Ustekinumab Severity of illness Medicine Humans Multicenter Studies as Topic 030212 general & internal medicine Randomized Controlled Trials as Topic Dose-Response Relationship Drug business.industry Middle Aged medicine.disease humanities Infectious Diseases Treatment Outcome Female Dermatologic Agents business medicine.drug |
| Zdroj: | Journal of the European Academy of Dermatology and Venereology : JEADV. 33(6) |
| ISSN: | 1468-3083 |
| Popis: | BACKGROUND: Efficacy of tildrakizumab for plaque psoriasis was demonstrated in randomized, placebo-controlled trials. OBJECTIVE: To consolidate tildrakizumab efficacy results by pooling data. METHODS: Data (N = 2081) from tildrakizumab 100 mg, tildrakizumab 200 mg and placebo groups in three trials were pooled. RESULTS: Proportions of Psoriasis Area and Severity Index (PASI) 75 responders at week 12 were better with tildrakizumab 100 mg (62.3%) and tildrakizumab 200 mg (64.8%) vs. placebo (5.6%; P < 0.0001) and for PASI 90, PASI 100 and Physician's Global Assessment (PGA) 'clear' or 'minimal' vs. placebo (P < 0.0001). Responses increased from weeks 12 to 28. Week 12 PASI and PGA responses to tildrakizumab vs. placebo were numerically greater in patients with lower vs. higher bodyweight and were better with tildrakizumab 200 mg than tildrakizumab 100 mg for patients with higher bodyweight. Week 12 PASI 75 responses vs. placebo with tildrakizumab 100 mg were similar between patients with (55.0%) or without (56.7%) prior biologics. PASI 90, PASI 100 and PGA responses were generally higher in patients without prior biologics. Week 8 PASI 50 response predicted PASI 90 response. CONCLUSION: Pooled data confirmed the efficacy of tildrakizumab for moderate-to-severe plaque psoriasis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text